Where Can You Actually Get Semaglutide Microdosing? 7 Real Options in 2026

Where can you get semaglutide microdosing? Seven real options

Most search results for semaglutide microdosing are articles and forum threads, not something you can buy. Strip those out, and seven services remain with a priced low-dose plan. Here is which one fits whom.

• Cheapest month to month: Mochi Health, about $140 a month at its lowest dose.
• Built-in coaching: Noom, about $180 a month.
• Same price at every dose: BetterMe Rx, about $145 a month if you pay a year upfront.
• Brand-name drug: Hims, with the FDA-approved Wegovy pill.
• With private insurance: Mochi's Covered With Mochi plan bills your visits to the plan. The membership then drops under $20 a month, and you pay cash for the medicine.

Mochi Health: the lowest monthly price at a low dose

Mochi has a microdose page, but no separate microdose price. It prices compounded semaglutide by dose, plus a $79 monthly membership. At the lowest dose, the total is about $140 a month. The next dose up adds about $10.

New members get the first month of membership free, though not in every state. That makes month one about $60 at the lowest dose. Paying a year of membership upfront brings the monthly cost to about $110. Mochi now works like a pharmacy marketplace, so medicine prices can vary by pharmacy.

Noom's Microdose GLP-1Rx: the best-known plan

Noom built the best-known branded version. Microdose GLP-1Rx is its own plan, and it uses compounded semaglutide only. The first four weeks cost $79. After that, it costs about $180 a month. Noom bills it as one charge of about $540 every 12 weeks, so plan for that lump sum.

Noom says doses usually run from about 0.2 mg to about 0.6 mg a week. A clinician sets the dose for each member. Noom's coaching app is included in the price.

Noom also sells Proactive Health, a low-dose plan aimed at overall health more than weight loss. It costs about $150 every 4 weeks. It caps semaglutide at 0.2 mg a week and adds an at-home blood test of 17 health markers. It is open to adults with a BMI of 21 or more. BMI is a weight-for-height score.

Noom's marketing drew a formal challenge. In May 2026, the National Advertising Division, an industry watchdog for ad claims, reviewed a complaint from Eli Lilly. At issue was Noom's slogan, "A Smaller Dose. A Smarter Start." The NAD found Noom hadn't proven that a smaller dose brings a measurable health benefit. Noom said it disagreed, but agreed to change or drop the claim.

BetterMe Rx: one price at every dose

BetterMe Rx sells a separate microdosing plan for people who want to lose 5 to 20 pounds or keep weight off. It uses low-dose compounded semaglutide shots. It costs about $205 month to month. On a 12-month plan, it drops to about $145 a month, paid as one charge of $1,740. A daily tablet version is sold at about the same price. The price stays the same as the dose changes. Visits and shipping are included.

Read its marketing with care. Its microdosing page quotes weight loss of up to 16%. That figure reflects full-dose treatment, not microdoses. Month to month, the microdose plan also costs a little more than BetterMe's standard semaglutide plan. Nothing is refunded once an order is processed. Its Trustpilot score is a mixed 3.6 out of 5.

Hims: a brand-name Wegovy pill plan

Hims is the only option here with an FDA-approved drug. Its microdosing plan uses the Wegovy pill at 1.5 mg to 4 mg a day. At 1.5 mg, the pill costs about $150 a month. At 4 mg, it costs about $200. A required membership adds about $150 a month, so expect about $300 to $350 in total. The first month of membership is $39, which brings month one to about $190.

Hims calls the plan off-label, meaning a use the FDA label doesn't cover. It isn't offered in every state. On the label, 1.5 mg and 4 mg are only starting steps on the way to 25 mg. Staying on them long term hasn't been tested for weight loss.

There is also a legal cloud. In July 2026, the FTC, Utah and California sued Hims & Hers. The case is about hard-to-cancel subscriptions and sharing health data with ad platforms. The company denies the claims, and the case is still pending. See our Hims review.

Lemonaid Health: a firm 25% dose cap

Lemonaid Health sells compounded semaglutide microdoses for $199 a month. A required membership adds $49 a month, so the total is about $250. Lemonaid caps the dose at 25% of a standard maintenance dose. Noom draws the same line. That shared cap is an informal habit among a few sellers, not a medical standard.

Henry Meds: a microdose page without a set price

Henry Meds has a dedicated microdose page for compounded semaglutide shots. The page says GLP-1 prices vary by plan and dose, starting at $179 a month. Visits, medicine and supplies are included. That $179 is the lowest price across Henry's GLP-1 plans, so ask for the microdose price on your plan. If you prepay several months and cancel, Henry may ask you to pay out the balance. The exception is when a provider finds a medical reason to stop.

Fridays: sold for wellness, not weight loss

Fridays keeps its microdosing line apart from its weight-loss plans. It sells it for energy, focus and metabolic balance. Its semaglutide version is a daily oral blend that mixes semaglutide with other ingredients. It costs about $250 a month. Fridays itself says these formulas haven't been studied for those outcomes. The Better Business Bureau rates it F, with many unanswered refund complaints.

Not on the list: Ro and Alloy

Two other names come up often. Ro states on its site that it doesn't offer GLP-1 microdosing. Alloy, a menopause-focused service, has no separate microdose product. It sells compounded semaglutide in its standard weight plan, where the doctor sets the dose. Its doctors focus on perimenopause and menopause. See Alloy's weight-care plan for its prices.

What does semaglutide microdosing cost over a year?

The shape of the bill differs more than the total. These first-year figures assume you stay on a low dose.

• Mochi Health: about $1,310 with a prepaid year of membership. Month to month, about $1,590, counting the free first month.
• BetterMe Rx: about $1,740 paid upfront, or about $2,460 month to month.
• Noom Proactive Health: about $1,940, paid as 13 charges of about $150.
• Noom Microdose GLP-1Rx: about $2,230, counting the $79 first four weeks and four 12-week bills.
• Lemonaid Health: about $2,980.
• Fridays: about $2,990.
• Hims: about $3,470 at 1.5 mg, or about $4,070 at 4 mg, membership included.
• Henry Meds: no yearly figure, because Henry doesn't publish a microdose price.

None of these totals include lab tests your prescriber may order. Insurance doesn't pay for compounded medicine. Medicare's GLP-1 Bridge charges $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, for people who qualify. It runs through Medicare, not through these plans. For the wider price picture, the cheapest semaglutide providers compares more programs.

What actually counts as a semaglutide microdose?

Start with the brand names, because they trip up almost everyone. Ozempic and Wegovy are both semaglutide, sold under two names for two approvals. Ozempic is approved for type 2 diabetes and tops out at 2 mg a week. Wegovy is approved for weight management. Its usual maintenance dose is 2.4 mg a week. Neither brand sells a product called a microdose.

When a service advertises microdosing, it usually means compounded semaglutide. That's a pharmacy-made version of the same medicine, mixed in smaller amounts. The prescriber sets the schedule, not the FDA label. Hims is the exception, with low doses of the FDA-approved Wegovy pill. There is no FDA definition of a microdose. Noom and Lemonaid both define it as 25% or less of a typical maintenance dose.

The FDA's Wegovy dose ladder, and where a microdose sits below it

Wegovy's approved schedule is the yardstick for every microdose plan. The shot climbs in five steps to a 2.4 mg maintenance dose over at least 16 weeks. A compounded microdose usually stays at or below the lower steps. Sometimes it sits under the very first one.

For the full ladder, the pill's own schedule and missed-dose rules, see the complete semaglutide dosage guide.

How does a semaglutide microdosing protocol work?

In every legitimate version, a prescriber sets the dose, not you. Noom runs each dose through a clinician review before anything ships. Henry Meds and Fridays describe the same shape. You get a first evaluation and a starting dose. The provider then adjusts it based on how you feel on it.

Where plans differ is pace. Some treat microdosing as a gentler on-ramp, like the FDA schedule but slower. Others, Fridays' wellness line especially, treat it as a place to stay long term. Ask which one you're buying before you start.

Is there real science behind semaglutide microdosing?

There is a real mechanism and some early dose data, but no trial of microdose plans as sold. Semaglutide works on the GLP-1 receptor, which helps control appetite and blood sugar. That action is well understood.

The closest evidence is a 2018 dose-finding trial of daily semaglutide shots, published in The Lancet. Its lowest dose, 0.05 mg a day, adds up to about 0.35 mg a week. People on that dose lost 6.0% of their weight in a year. People on placebo lost 2.3%. Higher doses brought more weight loss, up to 13.8% at the top dose.

That trial used daily shots, not the weekly schedule these plans use. It also lasted one year, so it says nothing about staying low for longer. STEP 1, the trial behind Wegovy, tested only the 2.4 mg dose. Several companies have built whole product lines on the microdose idea. Sales are not evidence, and Noom's May 2026 NAD case is a good reminder of the difference.

Are side effects gentler at a microdose, and does it still work?

Probably somewhat gentler. In the 2018 dose-finding trial, stomach side effects, mostly nausea, rose with the dose. In Wegovy's trials, nausea and stomach upset hit hardest right after each dose increase, then eased. So a smaller dose should feel easier. Noom's own figures come from members' self-reported data, not a trial. For side-effect rates at standard doses, see semaglutide side effects.

On results, the lower you go, the less you can count on. In the 2018 trial, weight loss grew with the dose. The lowest dose still beat placebo, but by much less. How much a weekly microdose delivers over several years isn't known.

Can semaglutide microdosing help with inflammation or autoimmune symptoms?

This part of the pitch deserves the most doubt. Immune cells do carry GLP-1 receptors. In lab and animal studies, semaglutide lowered some inflammation markers. That's real biology. But it's a long way from treating rheumatoid arthritis, Hashimoto's or lupus in a person on a fraction of a dose. No completed human trial shows that microdosing improves an autoimmune or inflammatory disease. Treat that claim as unstudied.

Is microdosing the right starting point in perimenopause?

Some women find their stomach touchier in perimenopause, with more nausea and bloating than before. If that's you, a gentler start has real appeal. A slower climb can mean fewer rough early weeks. Muscle is the other thing to watch at any dose, since it gets harder to keep after 40. GLP-1s and muscle loss in perimenopause covers how to protect it.

The trade-off is certainty. Staying at a fraction of the studied dose gives up some confidence about results. If real weight or metabolic change is your main goal, Wegovy's full label doses have the strongest evidence. A slower climb toward those doses is a middle path worth raising if side effects worry you.

How to tell a legitimate low-dose plan from a DIY red flag

What matters isn't the number on the dose but who manages it. A legitimate plan comes from a licensed prescriber and a named pharmacy. Your provider sets the dose and adjusts it. These are the red flags:

• Splitting a Wegovy or Ozempic pen yourself. Brand-name pens deliver preset doses and aren't designed to be split.
• Buying an unlabeled "microdosing kit" online. You can't know what is in it or how strong it is.
• Drawing a smaller amount from a vial on your own. Do it only with instructions from a prescriber who knows your history.

The FDA has documented what goes wrong. In July 2024, it warned about compounded semaglutide dosing errors. Some patients injected 5 to 20 times their intended dose after mixing up syringe units. Some needed hospital care. That risk comes with vials and syringes, not with preset brand-name pens.

Compounding rules have also narrowed. A 503A pharmacy mixes a drug for one patient's prescription. A 503B outsourcing facility makes larger batches. The FDA declared the semaglutide shortage over in February 2025, which ended the grace period for both. Compounding is now meant for when an approved drug doesn't meet a patient's medical need.

In April 2026, the FDA also proposed not adding semaglutide, tirzepatide and liraglutide to its 503B bulk-drug list. The comment period closed July 30, 2026, with no final decision yet. If a seller won't tell you which pharmacy fills your order, walk away.